Intricacies of aetiology in intrafamilial degenerative disease

Jessica L Lowry, Éanna B Ryan, Y Taylan Esengul, Nailah Siddique, Teepu Siddique, Jessica L Lowry, Éanna B Ryan, Y Taylan Esengul, Nailah Siddique, Teepu Siddique

Abstract

The genetic underpinnings of late-onset degenerative disease have typically been determined by screening families for the segregation of genetic variants with the disease trait in affected, but not unaffected, individuals. However, instances of intrafamilial etiological heterogeneity, where pathogenic variants in a culprit gene are not shared among all affected family members, continue to emerge and confound gene-discovery and genetic counselling efforts. Discordant intrafamilial cases lacking a mutation shared by other affected family members are described as disease phenocopies. This description often results in an over-simplified acceptance of an environmental cause of disease in the phenocopy cases, while the role of intrafamilial genetic heterogeneity, shared de novo mutations or epigenetic aberrations in such families is often ignored. On a related note, it is now evident that the same disease-associated variant can be present in individuals exhibiting clinically distinct phenotypes, thereby genetically uniting seemingly unrelated syndromes to form a spectrum of disease. Herein, we discuss the intricacies of determining complex degenerative disease aetiology and suggest alternative mechanisms of disease transmission that may account for the apparent missing heritability of disease.

Keywords: aetiology; inheritance; neurodegeneration; phenocopy; pleiotropy.

© The Author(s) (2020). Published by Oxford University Press on behalf of the Guarantors of Brain.

Figures

Graphical Abstract
Graphical Abstract
Figure 1
Figure 1
Family 379. Unaffected individuals are represented by white diamonds. For simplicity and clarity, multiple unaffected individuals within a sibship are represented by a single diamond and spouses are omitted. All affected individuals in this pedigree have a clinical diagnosis of ALS. Affected individuals for which DNA samples were unavailable are represented by grey diamonds. Affected family members with a TAR DNA-binding protein 43 p. G298S mutation are represented by black diamonds. Affected individual III-6 (yellow diamond) harbours a heterozygous SOD1 p. D91A mutation. Affected individuals IV-30 and V-3 (red diamonds) lack a mutation in known ALS-associated genes. Individual IV-25 is a true obligate carrier of TAR DNA-binding protein 43 p. G298S. All other indicated obligate carriers, represented by a black circle within a diamond, are possible obligate carriers since DNA samples were unavailable to confirm the presence of a mutation or the affected individuals in subsequent generations lack a known mutation.
Figure 2
Figure 2
Family 1174. Unaffected individuals are represented by white diamonds. For simplicity and clarity, multiple unaffected individuals within a sibship are represented by a single diamond and spouses are omitted. Individuals affected with ALS for which DNA samples were unavailable are represented by grey diamonds. Individuals affected with ALS for which DNA samples are available are represented by black diamonds. Individual V-1, represented by a yellow diamond, presented with bilateral leg weakness at 45 years of age and has a clinical diagnosis of spastic paraparesis with lower extremity weakness. Their condition has been stable for 30 years. Individual V-6, represented by a green diamond, has a clinical diagnosis of probable Alzheimer Disease. Individual V-13, represented by a red diamond, has a clinical diagnosis of Paget Disease of Bone. SQSTM1 p. P392L-positive individuals are indicated by a ‘+’ sign. SQSTM1 p. P392L-negative individuals are indicated by a ‘−’ sign. Possible obligate carriers are represented by a black circle within a diamond.
Figure 3
Figure 3
A hypothetical pedigree depicting scenarios to consider when encountering cases of presumed discordant disease aetiology. We indicate three siblings with a clinically similar phenotype (black). Two of the three affected individuals (II-3 and II-4) harbour a candidate disease-causing variant W, whereas all others tested negative for variant W in blood. While the phenotype in individual II-5 may be the result of an environmental trigger (i.e. classical phenocopy), the apparent disconnect between genotype and phenotype may also be explained by intrafamilial genetic heterogeneity (variants W and X), chimerism, mosaicism or identification of a distinct shared disease-causing variant Y. Alternatively, variant Z may have pleiotropic functions, and therefore cause a clinically distinct phenotype (red and black). In situations where both parents appear healthy and/or test negative for the suspected disease-causing variant, one must consider the potential role of germline chimerism or germline mosaicism via DNMs or epimutations.

References

    1. Acuna-Hidalgo R, Veltman JA, Hoischen A. New insights into the generation and role of de novo mutations in health and disease. Genome Biol 2016; 17: 241.
    1. Ajroud-Driss S, Fecto F, Ajroud K, Lalani I, Calvo SE, Mootha VK, et al. Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a family with autosomal dominant mitochondrial myopathy. Neurogenetics 2015; 16: 1–9.
    1. Ajroud-Driss S, Siddique T. Sporadic and hereditary amyotrophic lateral sclerosis (ALS). Biochim Biophys Acta 2015; 1852: 679–84.
    1. Al-Chalabi A. Perspective: don't keep it in the family. Nature 2017; 550: S112.
    1. Al-Chalabi A. Recessive amyotrophic lateral sclerosis families with the D90A SOD1 mutation share a common founder: evidence for a linked protective factor. Hum Mol Genet 1998; 7: 2045–50.
    1. Al-Chalabi A, van den Berg LH, Veldink J. Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol 2017; 13: 96–104.
    1. Alexander MD, Traynor BJ, Miller N, Corr B, Frost E, McQuaid S, et al. “True” sporadic ALS associated with a novel SOD-1 mutation. Ann Neurol 2002; 52: 680–3.
    1. Andersen PM, Nilsson P, Ala-Hurula V, Keränen M-L, Tarvainen I, Haltia T, et al. Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase. Nat Genet 1995; 10: 61–6.
    1. Bannwarth S, Ait-El-Mkadem S, Chaussenot A, Genin EC, Lacas-Gervais S, Fragaki K, et al. A mitochondrial origin for frontotemporal dementia and amyotrophic lateral sclerosis through CHCHD10 involvement. Brain 2014; 137: 2329–45.
    1. Beck J, Poulter M, Hensman D, Rohrer JD, Mahoney CJ, Adamson G, et al. Large C9orf72 hexanucleotide repeat expansions are seen in multiple neurodegenerative syndromes and are more frequent than expected in the UK population. Am J Hum Genet 2013; 92: 345–53.
    1. Belzil VV, Katzman RB, Petrucelli L. ALS and FTD: an epigenetic perspective. Acta Neuropathol 2016; 132: 487–502.
    1. Betarbet R, Greenamyre JT. Parkinson's disease: animal models. Handb Clin Neurol 2007; 83: 265–87.
    1. Blake GE, Watson ED. Unravelling the complex mechanisms of transgenerational epigenetic inheritance. Curr Opin Chem Biol 2016; 33: 101–7.
    1. Bohacek J, Mansuy IM. Epigenetic risk factors for diseases: a transgenerational perspective In: Dietmar S, Elisabeth B, editors. Epigenetics and neuroendocrinology: clinical focus on psychiatry, Vol. 2 Cham: Springer International Publishing; 2016. p. 79–119.
    1. Bories C, Amendola J, Lamotte d'Incamps B, Durand J. Early electrophysiological abnormalities in lumbar motoneurons in a transgenic mouse model of amyotrophic lateral sclerosis. Eur J Neurosci 2007; 25: 451–9.
    1. Boskovic A, Rando OJ. Transgenerational epigenetic inheritance. Annu Rev Genet 2018; 52: 21–41.
    1. Bucelli RC, Arhzaouy K, Pestronk A, Pittman SK, Rojas L, Sue CM, et al. SQSTM1 splice site mutation in distal myopathy with rimmed vacuoles. Neurology 2015; 85: 665–74.
    1. Cady J, Allred P, Bali T, Pestronk A, Goate A, Miller TM, et al. Amyotrophic lateral sclerosis onset is influenced by the burden of rare variants in known amyotrophic lateral sclerosis genes. Ann Neurol 2015; 77: 100–13.
    1. Calvo A, et al. De novo nonsense mutation of the FUS gene in an apparently familial amyotrophic lateral sclerosis case. Neurobiol Aging 2014; 35: 1513.e7.
    1. Campbell IM, Shaw CA, Stankiewicz P, Lupski JR. Somatic mosaicism: implications for disease and transmission genetics. Trends Genet 2015; 31: 382–92.
    1. Chang Q, Martin LJ. Glycine receptor channels in spinal motoneurons are abnormal in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2011; 31: 2815–27.
    1. Chesi A, Staahl BT, Jovičić A, Couthouis J, Fasolino M, Raphael AR, et al. Exome sequencing to identify de novo mutations in sporadic ALS trios. Nat Neurosci 2013; 16: 851–5.
    1. Chio A, et al. A de novo missense mutation of the FUS gene in a “true” sporadic ALS case. Neurobiol Aging 2011; 32: 553.e23.
    1. Chong S, Youngson NA, Whitelaw E. Heritable germline epimutation is not the same as transgenerational epigenetic inheritance. Nat Genet 2007; 39: 574–5; author reply 75–6.
    1. Cirulli ET, Lasseigne BN, Petrovski S, Sapp PC, Dion PA, Leblond CS, et al. Exome sequencing in amyotrophic lateral sclerosis identifies risk genes and pathways. Science 2015; 347: 1436–41.
    1. Cooper-Knock J, Robins H, Niedermoser I, Wyles M, Heath PR, Higginbottom A, et al. Targeted genetic screen in amyotrophic lateral sclerosis reveals novel genetic variants with synergistic effect on clinical phenotype. Front Mol Neurosci 2017; 10: 370.
    1. Daxinger L, Whitelaw E. Understanding transgenerational epigenetic inheritance via the gametes in mammals. Nat Rev Genet 2012; 13: 153–62.
    1. DeJesus-Hernandez M, Kocerha J, Finch N, Crook R, Baker M, Desaro P, et al. De novo truncating FUS gene mutation as a cause of sporadic amyotrophic lateral sclerosis. Hum Mutat 2010; 31: E1377–89.
    1. DeJesus-Hernandez M, Mackenzie IR, Boeve BF, Boxer AL, Baker M, Rutherford NJ, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011; 72: 245–56.
    1. Delamarre A, Meissner WG. Epidemiology, environmental risk factors and genetics of Parkinson's disease. Presse Med 2017; 46: 175–81.
    1. Deng H-X, Chen W, Hong S-T, Boycott KM, Gorrie GH, Siddique N, et al. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011; 477: 211–5.
    1. Deng H-X, Pericak-Vance MA, Siddique T. Reply to ‘TMEM230 variants in Parkinson’s disease' and ‘doubts about TMEM230 as a gene for parkinsonism’. Nat Genet 2019; 51: 369–71.
    1. Deng H-X, Shi Y, Yang Y, Ahmeti KB, Miller N, Huang C, et al. Identification of TMEM230 mutations in familial Parkinson's disease. Nat Genet 2016; 48: 733–9.
    1. Dobson-Stone C, Luty AA, Thompson EM, Blumbergs P, Brooks WS, Short CL, et al. Frontotemporal dementia–amyotrophic lateral sclerosis syndrome locus on chromosome 16p12.1-q12.2: genetic, clinical and neuropathological analysis. Acta Neuropathol 2013; 125: 523–33.
    1. Dobson-Stone C, Hallupp M, Shahheydari H, Ragagnin AMG, Chatterton Z, Carew-Jones F, et al. CYLD is a causative gene for frontotemporal dementia–amyotrophic lateral sclerosis. Brain 2020; 143: 783–99.
    1. Dols-Icardo O, García-Redondo A, Rojas-García R, Sánchez-Valle R, Noguera A, Gómez-Tortosa E, et al. Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia. Hum Mol Genet 2014; 23: 749–54.
    1. Donkin I, Barres R. Sperm epigenetics and influence of environmental factors. Mol Metab 2018; 14: 1–11.
    1. Dunham-Snary KJ, Ballinger SW. GENETICS. Mitochondrial-nuclear DNA mismatch matters. Science 2015; 349: 1449–50.
    1. Edens BM, Yan J, Miller N, Deng H-X, Siddique T, Ma YC, et al. A novel ALS-associated variant in UBQLN4 regulates motor axon morphogenesis. Elife 2017; 6: e25453.
    1. Elden AC, Kim H-J, Hart MP, Chen-Plotkin AS, Johnson BS, Fang X, et al. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. Nature 2010; 466: 1069–75.
    1. Fecto F. SQSTM1 mutations in familial and sporadic amyotrophic lateral sclerosis. Arch Neurol 2011; 68: 1440–6.
    1. Filipchuk AA, Durand J. Postnatal dendritic development in lumbar motoneurons in mutant superoxide dismutase 1 mouse model of amyotrophic lateral sclerosis. Neuroscience 2012; 209: 144–54.
    1. Gapp K, Jawaid A, Sarkies P, Bohacek J, Pelczar P, Prados J, et al. Implication of sperm RNAs in transgenerational inheritance of the effects of early trauma in mice. Nat Neurosci 2014; 17: 667–9.
    1. Heard E, Martienssen RA. Transgenerational epigenetic inheritance: myths and mechanisms. Cell 2014; 157: 95–109.
    1. Hesson LB, Hitchins MP, Ward RL. Epimutations and cancer predisposition: importance and mechanisms. Curr Opin Genet Dev 2010; 20: 290–8.
    1. Horsthemke B. A critical view on transgenerational epigenetic inheritance in humans. Nat Commun 2018; 9: 2973.
    1. Hwang JY, Aromolaran KA, Zukin RS. The emerging field of epigenetics in neurodegeneration and neuroprotection. Nat Rev Neurosci 2017; 18: 347–61.
    1. Iacoangeli A, Al Khleifat A, Jones AR, Sproviero W, Shatunov A, Opie-Martin S, et al. C9orf72 intermediate expansions of 24–30 repeats are associated with ALS. Acta Neuropathol Commun 2019; 7: 115.
    1. Imbert G, Saudou F, Yvert G, Devys D, Trottier Y, Garnier J-M, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996; 14: 285–91.
    1. Jiao B, Xiao T, Hou L, Gu X, Zhou Y, Zhou L, et al. High prevalence of CHCHD10 mutation in patients with frontotemporal dementia from China. Brain 2016; 139: e21.
    1. Johnson JO, Mandrioli J, Benatar M, Abramzon Y, Van Deerlin VM, Trojanowski JQ, et al. Exome sequencing reveals VCP mutations as a cause of familial ALS. Neuron 2010; 68: 857–64.
    1. Kim HJ, Kim NC, Wang Y-D, Scarborough EA, Moore J, Diaz Z, et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 2013; 495: 467–73.
    1. Klein C, Chuang R, Marras C, Lang AE. The curious case of phenocopies in families with genetic Parkinson's disease. Mov Disord 2011; 26: 1793–802.
    1. Kun-Rodrigues C, Ganos C, Guerreiro R, Schneider SA, Schulte C, Lesage S, et al. A systematic screening to identify de novo mutations causing sporadic early-onset Parkinson's disease. Hum Mol Genet 2015; 24: 6711–20.
    1. Kwok CT, Morris A, de Belleroche JS. Sequestosome-1 (SQSTM1) sequence variants in ALS cases in the UK: prevalence and coexistence of SQSTM1 mutations in ALS kindred with PDB. Eur J Hum Genet 2014; 22: 492–6.
    1. Laurin N, Brown JP, Morissette J, Raymond V. Recurrent mutation of the gene encoding Sequestosome 1 (SQSTM1/p62) in Paget disease of bone. Am J Hum Genet 2002; 70: 1582–8.
    1. Le Ber I, Camuzat A, Guerreiro R, Bouya-Ahmed K, Bras J, Nicolas G, et al. SQSTM1 mutations in French patients with frontotemporal dementia or frontotemporal dementia with amyotrophic lateral sclerosis. JAMA Neurol 2013; 70: 1403–10.
    1. Leblond CS, Webber A, Gan-Or Z, Moore F, Dagher A, Dion PA, et al. De novo FUS P525L mutation in Juvenile amyotrophic lateral sclerosis with dysphonia and diplopia. Neurol Genet 2016; 2: e63.
    1. Lee M-H, Siddoway B, Kaeser GE, Segota I, Rivera R, Romanow WJ, et al. Somatic APP gene recombination in Alzheimer's disease and normal neurons. Nature 2018; 563: 639–45.
    1. Lucking CB, Dürr A, Bonifati V, Vaughan J, De Michele G, Gasser T, Harhangi BS, et al. Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med 2000; 342: 1560–7.
    1. Luo S, Valencia CA, Zhang J, Lee N-C, Slone J, Gui B, et al. Biparental inheritance of mitochondrial DNA in humans. Proc Natl Acad Sci USA 2018; 115: 13039–44.
    1. MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, Abecasis GR, et al. Guidelines for investigating causality of sequence variants in human disease. Nature 2014; 508: 469–76.
    1. Majounie E, Renton AE, Mok K, Dopper EG, Waite A, Rollinson S, et al. Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study. Lancet Neurol 2012; 11: 323–30.
    1. Martin E, Cazenave W, Cattaert D, Branchereau P. Embryonic alteration of motoneuronal morphology induces hyperexcitability in the mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2013; 54: 116–26.
    1. Maruyama H, Morino H, Ito H, Izumi Y, Kato H, Watanabe Y, et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010; 465: 223–6.
    1. Mayr WR, Pausch V, Schnedl W. Human chimaera detectable only by investigation of her progeny. Nature 1979; 277: 210–11.
    1. Milan L, Barrière G, De Deurwaerdère P, Cazalets J-R, Bertrand SS. Monoaminergic control of spinal locomotor networks in SOD1G93A newborn mice. Front Neural Circuits 2014; 8: 77.
    1. Miranda-Morales E, Meier K, Sandoval-Carrillo A, Salas-Pacheco J, Vázquez-Cárdenas P, Arias-Carrión O, et al. Implications of DNA methylation in Parkinson's disease. Front Mol Neurosci 2017; 10: 225.
    1. Naruse H, Ishiura H, Mitsui J, Takahashi Y, Matsukawa T, Tanaka M, et al. Burden of rare variants in causative genes for amyotrophic lateral sclerosis (ALS) accelerates age at onset of ALS. J Neurol Neurosurg Psychiatry 2019; 90: 537–42.
    1. Pambo-Pambo A, Durand J, Gueritaud JP. Early excitability changes in lumbar motoneurons of transgenic SOD1G85R and SOD1G(93A-low) mice. J Neurophysiol 2009; 102: 3627–42.
    1. Parton MJ, Broom W, Andersen PM, Al-Chalabi A, Nigel Leigh P, Powell JF, et al. D90A-SOD1 mediated amyotrophic lateral sclerosis: a single founder for all cases with evidence for a cis-acting disease modifier in the recessive haplotype. Hum Mutat 2002; 20: 473.
    1. Pasinelli P, Brown RH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci 2006; 7: 710–23.
    1. Penttila S, et al. Late onset spinal motor neuronopathy is caused by mutation in CHCHD10. Ann Neurol 2015; 77: 163–72.
    1. Polymeropoulos MH. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997; 276: 2045–7.
    1. Pulst S-M, Nechiporuk A, Nechiporuk T, Gispert S, Chen X-N, Lopes-Cendes I, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996; 14: 269–76.
    1. Puschmann A, Ross OA, Vilariño-Güell C, Lincoln SJ, Kachergus JM, Cobb SA, et al. A Swedish family with de novo alpha-synuclein A53T mutation: evidence for early cortical dysfunction. Parkinsonism Relat Disord 2009; 15: 627–32.
    1. Quinlan KA, Schuster JE, Fu R, Siddique T, Heckman CJ. Altered postnatal maturation of electrical properties in spinal motoneurons in a mouse model of amyotrophic lateral sclerosis. J Physiol 2011; 589: 2245–60.
    1. Rahbari R, Wuster A, Lindsay SJ, Hardwick RJ, Alexandrov LB, Al Turki S, et al. Timing, rates and spectra of human germline mutation. Nat Genet 2016; 48: 126–33.
    1. Rea SL, Majcher V, Searle MS, Layfield R. SQSTM1 mutations—bridging Paget disease of bone and ALS/FTLD. Exp Cell Res 2014; 325: 27–37.
    1. Renton AE, Majounie E, Waite A, Simón-Sánchez J, Rollinson S, Gibbs JR, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011; 72: 257–68.
    1. Rinkevich B. Human natural chimerism: an acquired character or a vestige of evolution? Hum Immunol 2001; 62: 651–7.
    1. Rohrer JD, Isaacs AM, Mizielinska S, Mead S, Lashley T, Wray S, et al. C9orf72 expansions in frontotemporal dementia and amyotrophic lateral sclerosis. Lancet Neurol 2015; 14: 291–301.
    1. Ross JP, Leblond CS, Catoire H, Volkening K, Strong M, Zinman L, et al. Somatic expansion of the C9orf72 hexanucleotide repeat does not occur in ALS spinal cord tissues. Neurol Genet 2019; 5: e317.
    1. Rubino E, Rainero I, Chio A, Rogaeva E, Galimberti D, Fenoglio P, et al. SQSTM1 mutations in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Neurology 2012; 79: 1556–62.
    1. Sharma A. Transgenerational epigenetics: integrating soma to germline communication with gametic inheritance. Mech Ageing Dev 2017; 163: 15–22.
    1. Sharma U. Paternal contributions to offspring health: role of sperm small RNAs in intergenerational transmission of epigenetic information. Front Cell Dev Biol 2019; 7: 215.
    1. Sheets KM, Baird ML, Heinig J, Davis D, Sabatini M, Starr DB, et al. A case of chimerism-induced paternity confusion: what ART practitioners can do to prevent future calamity for families. J Assist Reprod Genet 2018; 35: 345–52.
    1. Sloane MA, Ward RL, Hesson LB. Defining the criteria for identifying constitutional epimutations. Clin Epigenet 2016; 8: 39.
    1. Solovieff N, Cotsapas C, Lee PH, Purcell SM, Smoller JW. Pleiotropy in complex traits: challenges and strategies. Nat Rev Genet 2013; 14: 483–95.
    1. Steinberg KM, Yu B, Koboldt DC, Mardis ER, Pamphlett R. Exome sequencing of case-unaffected-parents trios reveals recessive and de novo genetic variants in sporadic ALS. Sci Rep 2015; 5: 9124.
    1. Storm CS, Kia DA, Almramhi M, Wood NW. Using Mendelian randomization to understand and develop treatments for neurodegenerative disease. Brain Commun 2020; 2: fcaa031.
    1. Swinnen B, Robberecht W. The phenotypic variability of amyotrophic lateral sclerosis. Nat Rev Neurol 2014; 10: 661–70.
    1. Taylor JP, Brown RH, Jr, Cleveland DW. Decoding ALS: from genes to mechanism. Nature 2016; 539: 197–206.
    1. Teyssou E, Takeda T, Lebon V, Boillée S, Doukouré B, Bataillon G, et al. Mutations in SQSTM1 encoding p62 in amyotrophic lateral sclerosis: genetics and neuropathology. Acta Neuropathol 2013; 125: 511–22.
    1. Tranah GJ. Mitochondrial-nuclear epistasis: implications for human aging and longevity. Ageing Res Rev 2011; 10: 238–52.
    1. Valente EM. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004; 304: 1158–60.
    1. van Blitterswijk M, van Es MA, Hennekam EAM, Dooijes D, van Rheenen W, Medic J, et al. Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 2012; 21: 3776–84.
    1. van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, Murray ME, Heckman MG, Diehl NN, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat expansions (Xpansize-72): a cross-sectional cohort study. Lancet Neurol 2013; 12: 978–88.
    1. van Doormaal PTC, Ticozzi N, Weishaupt JH, Kenna K, Diekstra FP, Verde F, et al. The role of de novo mutations in the development of amyotrophic lateral sclerosis. Hum Mutat 2017; 38: 1534–41.
    1. Vilarino-Guell C, Wider C, Ross OA, Dachsel JC, Kachergus JM, Lincoln SJ, et al. VPS35 mutations in Parkinson disease. Am J Hum Genet 2011; 89: 162–7.
    1. Watts GDJ, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant Valosin-containing protein. Nat Genet 2004; 36: 377–81.
    1. Williams ES, Barrett MJ, Dhamija R, Toran L, Chambers C, Mahadevan MS, et al. Phase determination using chromosomal microarray and fluorescence in situ hybridization in a patient with early onset Parkinson disease and two deletions in PRKN. Mol Genet Genomic Med 2018; 6: 457–62.
    1. Xi Z, van Blitterswijk M, Zhang M, McGoldrick P, McLean JR, Yunusova Y, et al. Jump from pre-mutation to pathologic expansion in C9orf72. Am J Hum Genet 2015; 96: 962–70.
    1. Yan W. Potential roles of noncoding RNAs in environmental epigenetic transgenerational inheritance. Mol Cell Endocrinol 2014; 398: 24–30.
    1. Zeybel M, Hardy T, Wong YK, Mathers JC, Fox CR, Gackowska A, et al. Multigenerational epigenetic adaptation of the hepatic wound-healing response. Nat Med 2012; 18: 1369–77.
    1. Zhu Z, Zhang F, Hu H, Bakshi A, Robinson MR, Powell JE, et al. Integration of summary data from GWAS and eQTL studies predicts complex trait gene targets. Nat Genet 2016; 48: 481–7.
    1. Zimprich A, Benet-Pagès A, Struhal W, Graf E, Eck SH, Offman MN, et al. A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. Am J Hum Genet 2011; 89: 168–75.
    1. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601–7.
    1. Zou ZY, Cui L-Y, Sun Q, Li X-G, Liu M-S, Xu Y, et al. De novo FUS gene mutations are associated with juvenile-onset sporadic amyotrophic lateral sclerosis in China. Neurobiol Aging 2013; 34: 1312.e1.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj